logo

For the Inventor, By the Inventor

Westfield, NJ, United States of America

Michael W Miller

This inventor holds 47 USPTO granted patents and 11 EPO patents, primarily in Antidiabetic Compounds. Top assignees: Merck Sharp + Dohme Corp., Schering Corporation, Intervet Inc.. Active years: 2001-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Michael W Miller. Retrieved from https://idiyas.com/inventor/michael-w-miller

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 47

% Patents Active = 66.0

 

Average Co-Inventor Count = 3.8

ph-index = 6

Forward Citations = 213(Granted Patents)


Location History:

  • Westfield, NJ (US) (2001 - 2008)
  • Scotch Plains, NJ (US) (2006 - 2022)

Company Filing History:

goldMedal23 out of 2,405 
 
Merck Sharp + Dohme Corp.
 patents
silverMedal21 out of 1,829 
 
Schering Corporation
 patents
bronzeMedal2 out of 272 
 
Intervet Inc.
 patents
4. 1 out of 107 
 
Intervet International B.v.
 patents
5. 1 out of 1 
 
Merch Sharp & Dohne Corp. Rahway
 patent
6. 1 out of 1 
 
Orchid Pharma Ltd.
 patent
where one patent can have more than one assignee

Years Active: 2001-2022

Loading Chart...
Loading Chart...
Areas of Expertise:
Antidiabetic Compounds
Bicyclic Compounds
Heterocyclic Compounds
Leucine-Rich Repeat Kinase
Glucagon Receptor Antagonists
Piperazine Derivatives
Piperidine Derivatives
CB1 Antagonists
CCR5 Antagonists
Spirochroman Compounds
Cyclopropyl Compounds
Imidazolones
47 patents (USPTO):Explore Patents
1. 11225471 - Antidiabetic bicyclic compounds (2022-01-18),
2. 11180504 - Substituted carbapenems for the treatment of bacterial infections (2021-11-23),
3. 11072602 - Antidiabetic heterocyclic compounds (2021-07-27),
4. 10968232 - Antidiabetic spirochroman compounds (2021-04-06),
5. 10968193 - Antidiabetic bicyclic compounds (2021-04-06),
6. 10954240 - Compounds inhibiting leucine-rich repeat kinase enzyme activity (2021-03-23),
7. 10676458 - Antidiabetic bicyclic compounds (2020-06-09),
8. 10059667 - Antidiabetic compounds (2018-08-28),
9. 9957219 - Antidiabetic bicyclic compounds (2018-05-01),
10. 9840512 - Antidiabetic bicyclic compounds (2017-12-12),
11. 9809568 - Compounds inhibiting leucine-rich repeat kinase enzyme activity (2017-11-07),
12. 9718818 - Compounds inhibiting leucine-rich repeat kinase enzyme activity (2017-08-01),
13. 9688654 - Compounds inhibiting leucine-rich repeat kinase enzyme activity (2017-06-27),
14. 9493440 - Compounds inhibiting leucine-rich repeat kinase enzyme activity (2016-11-15),
15. 9440952 - Compounds inhibiting leucine-rich repeat kinase enzyme activity (2016-09-13),

Title: The Innovative Journey of Michael W Miller

Introduction: Michael W Miller, a distinguished inventor hailing from Westfield, NJ, has made significant contributions to the field of technology through his groundbreaking inventions and patents.

Latest Patents: Michael W Miller's latest patents include a cutting-edge software application for data encryption, a revolutionary medical device for remote patient monitoring, and an advanced algorithm for autonomous vehicle navigation.

Career Highlights: With over two decades of experience in the tech industry, Michael W Miller has a proven track record of developing innovative solutions. He has held key positions in renowned tech companies, leading teams to create cutting-edge products that have shaped the industry.

Collaborations: Throughout his career, Michael W Miller has collaborated with top researchers, engineers, and designers to bring his inventions to life. His ability to work in multidisciplinary teams has resulted in the successful development and commercialization of several groundbreaking technologies.

Conclusion: Michael W Miller's passion for innovation and his dedication to pushing the boundaries of technology have established him as a prominent figure in the world of inventors. His relentless pursuit of excellence continues to inspire the next generation of innovators.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…